MENOPAUSAL THERAPY IN FOCUS — The FDA will hold a panel discussion Thursday on hormone therapy for menopausal women, a pet ...

A panel selected by FDA Commissioner Marty Makary, MD, MPH, unanimously urged the agency to remove the boxed warning on ...

A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

On Thursday in Washington, D.C., the U.S. Food and Drug Administration (FDA) convened a panel of top experts to reassess the ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

“The role of testosterone is just a lesson in gender bias,” says Kelly Casperson, MD, a urologist. “Because 100 percent of ...

The Food and Drug Administration is reassessing some warnings given about hormone therapy treatments for menopause that have ...

Puerto Rican Gov. Jennifer Gonzalez signed a bill into law that bans hormone therapy and gender-affirming surgeries for ...

Hormone therapy can be used to boost hormone levels and relieve menopause symptoms, which typically last an average of five years but can be as long as 10 years.

Overall, this suggests that the cumulative risk of breast cancer before age 55 for women taking estrogen/progestin is about 4.5%, compared with 4.1% among women who never used hormone therapy and 3.6% ...

An Food and Drug Administration expert panel on Thursday endorsed removing the "black box" warning on hormone treatments for ...